Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of VX-548 New Tablet Formulation
NCT05455502Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of suzetrigine in pain (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at 216 hours, Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration at 216 hours and 1 more. Started Jul 2022; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05455502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455502.